The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Phase 1
- Conditions
- DiarrheaMedullary Thyroid Cancer
- Interventions
- Drug: CASAD
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Salient Pharmaceuticals Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT01739634
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection
Phase 2
Terminated
- Conditions
- Diarrhoea, Clostridium Difficile
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Salient Pharmaceuticals Incorporated
- Target Recruit Count
- 2
- Registration Number
- NCT01570634
- Locations
- 🇺🇸
Scott & White Memorial Hospital, Temple, Texas, United States